Medscape September 6, 2024
(Reuters) – Eli Lilly’s experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.
Researchers reported at the recent European Society of Cardiology meeting in London that Lilly’s retatrutide significantly reduced patients’ blood lipid levels and cardiovascular risks in a mid-stage trial.
At 48 weeks, for example, retatrutide had reduced levels of triglycerides by up to 40.6%, and levels of a protein called apoC-III involved in glucose metabolism and inflammation by 38%.
Lilly had earlier announced that in the same trial patients taking injections of retatrutide at the highest dose had lost roughly 24% of their body weight, exceeding what the...
Today's Sponsors
Today's Sponsor